Abstract
The ectopic expression of the cell surface peptidase CD13 (aminopeptidase N) and of three other myelomonocytic antigens i.e. CD33, CD14 and CD15 was analyzed by flow cytometry in neoplastic lymphocytes from 81 consecutive patients with B-cell chronic lymphocytic leukemia (B-CLL). CD13 and CD14 antigens were detected on lymphocytes from 30% and 60% of patients respectively whilst a smaller percentage of samples was found positive for CD15 (5%) and CD33 (12%). The presence of CD13 and CD33 antigens on neoplastic B cells showed a statistically significant association with the two most important clinicopathologic prognostic factors in B-CLL: the clinical stage (CD13, p <0.01; CD33, p <0.05-Rai and Binet staging systems) and the pattern of bone marrow infiltration (CD13, p <0.001; CD33, p = 0.02). A multiple logistic regression analysis showed that the increased risk of CD13 positive patients (13.7 fold higher than in CD13 negative cases; p = 0.001) of presenting a diffuse pattern of bone marrow infiltration was independent from all other prognostic factors including sex, lymphocyte counts, age, and clinical stage. Our findings indicate for the first time a statistically significant association of CD13 and CD33 antigens with unfavorable prognostic factors in B-CLL. They suggest that the cross-lineage expression of myeloid-associated surface peptidases (CD13) and/or molecules related to cell adhesion processes (CD33), may influence the behaviour of B-cell chronic lymphoproliferative disorders in analogy to what is reported for acute leukemias and multiple myeloma.
| Original language | English |
|---|---|
| Pages (from-to) | 209-218 |
| Number of pages | 10 |
| Journal | Leukemia and Lymphoma |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- B-cell chronic lymphocytic leukemia
- Bone marrow infiltration
- CD13-Aminopeptidase N
- Myelomonocytic antigens
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
CD13 expression in b-cell chronic lymphocytic leukemia is associated with the pattern of bone marrow infiltration. / Pinto, Antonio; Zagonel, Vittorina; Carbone, Antonino; Serraino, Diego; Marotta, Giuseppe; Volpe, Rachele; Colombatti, Alfonso; Vecchio, Luigi Del.
In: Leukemia and Lymphoma, Vol. 6, No. 3, 1992, p. 209-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CD13 expression in b-cell chronic lymphocytic leukemia is associated with the pattern of bone marrow infiltration
AU - Pinto, Antonio
AU - Zagonel, Vittorina
AU - Carbone, Antonino
AU - Serraino, Diego
AU - Marotta, Giuseppe
AU - Volpe, Rachele
AU - Colombatti, Alfonso
AU - Vecchio, Luigi Del
PY - 1992
Y1 - 1992
N2 - The ectopic expression of the cell surface peptidase CD13 (aminopeptidase N) and of three other myelomonocytic antigens i.e. CD33, CD14 and CD15 was analyzed by flow cytometry in neoplastic lymphocytes from 81 consecutive patients with B-cell chronic lymphocytic leukemia (B-CLL). CD13 and CD14 antigens were detected on lymphocytes from 30% and 60% of patients respectively whilst a smaller percentage of samples was found positive for CD15 (5%) and CD33 (12%). The presence of CD13 and CD33 antigens on neoplastic B cells showed a statistically significant association with the two most important clinicopathologic prognostic factors in B-CLL: the clinical stage (CD13, p <0.01; CD33, p <0.05-Rai and Binet staging systems) and the pattern of bone marrow infiltration (CD13, p <0.001; CD33, p = 0.02). A multiple logistic regression analysis showed that the increased risk of CD13 positive patients (13.7 fold higher than in CD13 negative cases; p = 0.001) of presenting a diffuse pattern of bone marrow infiltration was independent from all other prognostic factors including sex, lymphocyte counts, age, and clinical stage. Our findings indicate for the first time a statistically significant association of CD13 and CD33 antigens with unfavorable prognostic factors in B-CLL. They suggest that the cross-lineage expression of myeloid-associated surface peptidases (CD13) and/or molecules related to cell adhesion processes (CD33), may influence the behaviour of B-cell chronic lymphoproliferative disorders in analogy to what is reported for acute leukemias and multiple myeloma.
AB - The ectopic expression of the cell surface peptidase CD13 (aminopeptidase N) and of three other myelomonocytic antigens i.e. CD33, CD14 and CD15 was analyzed by flow cytometry in neoplastic lymphocytes from 81 consecutive patients with B-cell chronic lymphocytic leukemia (B-CLL). CD13 and CD14 antigens were detected on lymphocytes from 30% and 60% of patients respectively whilst a smaller percentage of samples was found positive for CD15 (5%) and CD33 (12%). The presence of CD13 and CD33 antigens on neoplastic B cells showed a statistically significant association with the two most important clinicopathologic prognostic factors in B-CLL: the clinical stage (CD13, p <0.01; CD33, p <0.05-Rai and Binet staging systems) and the pattern of bone marrow infiltration (CD13, p <0.001; CD33, p = 0.02). A multiple logistic regression analysis showed that the increased risk of CD13 positive patients (13.7 fold higher than in CD13 negative cases; p = 0.001) of presenting a diffuse pattern of bone marrow infiltration was independent from all other prognostic factors including sex, lymphocyte counts, age, and clinical stage. Our findings indicate for the first time a statistically significant association of CD13 and CD33 antigens with unfavorable prognostic factors in B-CLL. They suggest that the cross-lineage expression of myeloid-associated surface peptidases (CD13) and/or molecules related to cell adhesion processes (CD33), may influence the behaviour of B-cell chronic lymphoproliferative disorders in analogy to what is reported for acute leukemias and multiple myeloma.
KW - B-cell chronic lymphocytic leukemia
KW - Bone marrow infiltration
KW - CD13-Aminopeptidase N
KW - Myelomonocytic antigens
UR - http://www.scopus.com/inward/record.url?scp=0026604912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026604912&partnerID=8YFLogxK
U2 - 10.3109/10428199209064897
DO - 10.3109/10428199209064897
M3 - Article
VL - 6
SP - 209
EP - 218
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -